Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2022 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: technetium who wrote (142)

7/1/2022 11:02:28 PM

From: technetium

1 Recommendation

Recommended By
BulbaMan

Read Replies (1) | Respond to of 267

Not surprisingly, last week's unalloyed good news (every contestant portfolio in the black, for I suspect the first time this year) was not repeated this week. The biotech indices losses were less than one percent, in comparison to the 4.1% haircut applied to the NASDAQ Composite. There were three stocks turning in gains greater than 50% for the week. Most of OMER’s gain was on Friday, on the basis of no obvious news on the wires. Likewise for CLVS (though they did have positive study results earlier in June). And the only news for AFIB were previously announced updates on a sale of IP and debt restructuring. The big loser for the week, RNLX, down 44%, seems to be only a reaction to the 3rd quarter financials (clearly not in line with “expectations”).

As far as the Contest Portfolios go, the median very slightly outperformed the biotech indices. Interestingly, the best portfolio for the week, BIO-TITAN achieved it without any of the top-5 holdings, just in overall performance of the portfolio. For the top ten, no change in the first four from last week. Both BIO-TITAN and JACK HARTMANN return after a one week absence, with BIO-TITAN parlaying their portfolio’s number one weekly performance by vaulting into fifth place YTD.

We have now reached the contest’s half way point, with the twenty-sixth weekly report, so maybe it’s worth a little look back. This has not been a great half year for stocks generally, and biotech have not escaped the downdraft. On five occasions, a single portfolio managed to creep into the black, YTD, but not since April 8th. Oh well. May you live in interesting times.

Twenty four of the 33 portfolios have made the top ten for at least one week. Two, DEW DILIGENCE and GENEGURU have been on it every week. DIEGOSAN has occupied the top spot fifteen times, including a run of thirteen uninterrupted Number Ones since April 8th.

Obviously, the first half year’s performance will matter yet, nonetheless, as all those stern warnings in the ads say, past performance is no guarantee for the future. Last year things were uncertain right up to the last few weeks. So, stay tuned!

		Report Time Ranges
			From	To
		Recent	6/24/22	7/1/22
		YTD	12/31/21	7/1/22
Index Performance
			Symbol	Recent	YTD
			^IXIC	-4.13%	-28.87%
			^NBI	-0.50%	-19.00%
			^SPSIBI	-0.74%	-31.58%
Share Performance
Recent				YTD
Top 5		Bottom 5		Top 5		Bottom 5
OMER	77.778%	RNLX	-43.982%	OPTN	124.69%	GNCA	-98.71%
CLVS	67.647%	AMRN	-25.000%	CBIO	95.84%	PRQR	-90.15%
AFIB	51.244%	BBLG	-21.299%	MACK	49.10%	PTE	-89.64%
VRCI.L	29.642%	NCNA	-21.186%	VRTX	30.84%	VLON	-89.63%
RIGL	22.549%	BBI	-20.776%	FENC	29.77%	AYLA	-86.92%
			Top 10 Portfolio YTD		YTD(Portfolio - SPSIBI)	Rec	Rec(Port. - SPSIBI)
			DIEGOSAN	-5.71%	25.87%	-0.343%	0.401%
			DEW DILIGENCE	-20.74%	10.84%	-2.466%	-1.722%
			KMASTRA	-24.11%	7.47%	0.158%	0.902%
			TECHNETIUM	-26.04%	5.54%	-0.117%	0.627%
			BIO-TITAN	-26.98%	4.60%	11.922%	12.666%
			GENEGURU	-30.78%	0.81%	-1.813%	-1.070%
			ROCKY9	-33.51%	-1.93%	-1.044%	-0.300%
			BIOSCIENTISTSA	-33.72%	-2.14%	-4.219%	-3.475%
			JACK HARTMANN	-33.90%	-2.32%	0.239%	0.983%
			TAMBORELLI	-34.33%	-2.74%	-1.208%	-0.464%
Average and Median Portfolio Performance
	Avg Recent	Avg YTD	Median Recent		Median YTD
	-$368	-37.84%	JFM WINTER	-$341	RKRW	-36.94%
	-0.56%	-37.84%	JFM WINTER	-0.496%	RKRW	-36.94%